PB2048: HEMATOLOGIC RECOVERY INDUCED BY AVATROMBOPAG IN SAA REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG

PB2048: HEMATOLOGIC RECOVERY INDUCED BY AVATROMBOPAG IN SAA REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG

Bibliographic Details
Main Authors:	Xiaoqing Liu, Yuemin Gong, Yue LI, Yawen Zhang, Xinyu Zhang, Qiqiang Long, Guangsheng He, Jianyong LI
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000974992.07304.d1

Similar Items

P763: EFFICACY AND SAFETY OF AVATROMBOPAG IN THE TREATMENT OF TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA
by: Ting Zhang, et al.
Published: (2023-08-01)

Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China
by: Zhuxin Zhang, et al.
Published: (2023-09-01)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
by: Zhuxin Zhang, et al.
Published: (2023-08-01)

P773: CYCLOPHOSPHAMIDE COMBINED WITH PREDNISONE FOR CYCLOSPORINE-REFRACTORY/RELAPSED T-LARGE GRANULAR LYMPHOCYTE LEUKEMIA ASSOCIATED PURE RED CELL APLASIA
by: Xiaoqing Liu, et al.
Published: (2023-08-01)

Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag
by: Ruixin Li, et al.
Published: (2022-05-01)

Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure
by: Abdul Rehman Arif, et al.
Published: (2022-11-01)

Avatrombopag for the salvage treatment of platelet transfusion refractoriness
by: Yuehong Qin, et al.
Published: (2024-03-01)

2048
by: Michio Taya, et al.
Published: (2017-09-01)

PB2479: ELTROMBOPAG, BUT NOT AVATROMBOPAG, REGULATES BONE MARROW MICROENVIRONMENT MIMICKING APLASTIC ANEMIA THROUGH DOWN-REGULATION OF FERROPTOSIS INHIBITOR
by: Jiang Ji, et al.
Published: (2023-08-01)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
by: Hong Chang, et al.
Published: (2023-11-01)

Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia
by: Yufei Zhao, et al.
Published: (2023-01-01)

Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant
by: Hong Tian, et al.
Published: (2022-08-01)

PB1947: ELTROMBOPAG COMBINED WITH IST AS A MULTICENTER STUDY OF THE FIRST LINE TREATMENT OF CHILDREN WITH SAA.
by: L. Yang, et al.
Published: (2022-06-01)

Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial
by: Ziqi Wan, et al.
Published: (2023-12-01)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors
by: Yanting Gao, et al.
Published: (2022-10-01)

PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM
by: Scott Kolodny, et al.
Published: (2023-08-01)

Cerebral venous thrombosis in refractory idiopathic thrombocytopenia treated with eltrombopag
by: Vivek Nambiar, et al.
Published: (2016-01-01)

PB2034: TARGETED SEQUENCING LANDSCAPE OF A CHINESE PURE RED CELL ANEMIA COHORT
by: Yue LI, et al.
Published: (2023-08-01)

HEMATOLOGIC RECOVERY INDUCED BY ELTROMBOPAG IN PATIENT WITH APLASTIC ANEMIA AFTER TEMOZOLOMIDE
by: ACP Silva, et al.
Published: (2023-10-01)

Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis
by: Yan Zhang, et al.
Published: (2024-04-01)

Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments
by: Andrea Aiello, et al.
Published: (2023-12-01)

2048 The hypertrophic cardiomyopathy phenotype revisited with cardiovasculara magnetic resonance
by: Manning Warren J, et al.
Published: (2008-10-01)

NATIONAL EXPERIENCE WITH IMMUNOSUPPRESSIVE THERAPY AND ELTROMBOPAG IN CHILDREN WITH APLASTIC ANEMIA- REAL WORLD DATA
by: Katarzyna Pawelec, et al.
Published: (2023-12-01)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
by: H. Chang, et al.
Published: (2022-06-01)

IMMUNOSUPPRESSIVE THERAPY IN A PATIENT WITH SAA-like RCC AND GATA2 DEFICIENCY
by: D Kroiss, et al.
Published: (2023-12-01)

Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation
by: Meng Zhou, et al.
Published: (2022-09-01)

Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials
by: Stephane Heritier, et al.
Published: (2024-01-01)

Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review
by: Danielle Francisco Honorato de Barros Torelli, et al.
Published: (2023-06-01)

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation
by: Semra Aydin, et al.
Published: (2020-10-01)

Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag
by: Mahmoud Abdelsamia, et al.
Published: (2023-09-01)

PB2048: EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER STUDY
by: C. Chen, et al.
Published: (2022-06-01)

PB2049: THE EFFICACY OF HETROMBOPAG PLUS CYCLOSPORINE A IN PATIENTS WITH TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A PROSPECTIVE REGISTRY STUDY
by: Yuemin Gong, et al.
Published: (2023-08-01)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
by: Ayşe Işık, et al.
Published: (2013-09-01)

Signal mining and analysis for adverse events of avatrombopag based on FAERS
by: XIONG Rui, et al.
Published: (2024-02-01)

PB2067: PROSPECTIVE SELF-CONTROL ANALYSIS OF GLUCOCORTICOID MAINTENANCE THERAPY FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
by: Hui Yang, et al.
Published: (2023-08-01)

Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial
by: Jiang Ji, et al.
Published: (2023-09-01)

Correlation of the Plasma Concentration of Eltrombopag With Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Centre Study in China
by: Wei Zuo, et al.
Published: (2020-11-01)

S184: SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA
by: Ashvind Prabahran, et al.
Published: (2023-08-01)

P811: A SINGLE CENTER HISTORICAL CONTROL STUDY OF ELTROMBOPAG ADDED TO IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA IN CHILDREN
by: B. yang, et al.
Published: (2022-06-01)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
by: Qi An, et al.
Published: (2023-08-01)